Zepbound vs Mounjaro: Where Both Sit in the GLP-1 Field

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

At the PlexusDx Education Hub we map the GLP-1 landscape, weight-management protocols, and the genetics underneath each metabolic choice. Browse all Peptides & GLP-1 education

This comparison is editorially independent. PlexusDx has no commercial relationship with the manufacturers of the products reviewed.

To make sense of Zepbound and Mounjaro, it helps to zoom out and place both within the broader incretin-therapy landscape rather than treating them as an isolated pair. Both are tirzepatide from Eli Lilly, and seeing where they sit among the other GLP-1 options clarifies what is actually being compared. This overview is current as of April 2026.

Placing both in the incretin landscape

The incretin-therapy field spans GLP-1-selective agonists (semaglutide, liraglutide, dulaglutide), GIP/GLP-1 dual agonists (tirzepatide), and investigational agents such as the triple agonist retatrutide, which is not FDA-approved. Within that map, Zepbound and Mounjaro occupy the same coordinate: both are tirzepatide, engaging the GIP and GLP-1 receptors to slow gastric emptying, temper post-meal glucose, and raise satiety signaling. They are two labels on one dual-agonist molecule.

Same active ingredient, divergent labels

Because the molecule is shared, the meaningful separation is regulatory. Across the field, FDA approvals fall by indication: Ozempic (2017) and Rybelsus (2019) for type 2 diabetes; Wegovy (2021) for weight management; Mounjaro (2022) for type 2 diabetes; Zepbound (2023) for weight management, extended in 2024 to obstructive sleep apnea; Trulicity (2014) and Victoza (2010) for type 2 diabetes. Mounjaro and Zepbound simply sit on the diabetes and weight-management sides of that line, respectively.

How the trial programs are built

The evidence base is program-structured: STEP (semaglutide, weight), SUSTAIN and SELECT (semaglutide, diabetes and cardiovascular), SURMOUNT and SURPASS (tirzepatide, weight and diabetes), SURMOUNT-OSA (sleep apnea), LEAD and LEADER (liraglutide), and AWARD (dulaglutide). Some pairings were tested directly — SUSTAIN 7 and SURPASS-2 — but populations, doses, and endpoints vary, so conclusions belong at the trial level rather than the class level.

Class-wide safety picture

Safety is largely a class property. Every FDA-approved GLP-1 receptor agonist and GIP/GLP-1 dual agonist carries the boxed warning for thyroid C-cell tumor risk seen in rodent studies, and all are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Gastrointestinal effects lead the common side effects; rare serious events include pancreatitis, gallbladder disease, and dehydration-related acute kidney injury.

Access and out-of-pocket reality

Access mirrors the indication split. As of April 2026, list prices for the FDA-approved brands range roughly $815 to $1,620 per month at U.S. list price (manufacturer published pricing). What a patient actually pays depends on insurance coverage, the indication on the prescription, savings-card eligibility, and whether a compounded alternative is available through a licensed compounding pathway.

The upstream genetic map

Underneath the entire landscape lies a shared genetic layer. Variants in FTO (fat-mass and obesity-associated), GLP1R (encoding the GLP-1 receptor), MC4R (central to energy balance), and TCF7L2 (tied to glucose homeostasis and GLP-1 secretion) shape the metabolic terrain any compound has to work within. These are pathway-level markers — they do not predict response to tirzepatide or any drug, but they map the biology a clinician prescribes into.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. Before any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights — including FTO, GLP1R, MC4R, and TCF7L2 variants that shape your baseline biology. That is the test before you invest approach.

Related reading on PlexusDx: Mounjaro Coupon without Insurance, Mounjaro Online, Mounjaro Medication, Mounjaro Coupon 25.

Disclaimer: This article is educational. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols and covers the mechanism, evidence, and genetic context that inform any decision to use them. PlexusDx does not sell, prescribe, or recommend any other GLP-1-category peptide beyond semaglutide and tirzepatide (including dulaglutide, liraglutide, retatrutide, cagrilintide, and related compounds). The Precision Peptide Genetic Test analyzes how your genes influence peptide-related pathways; it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Start with the biology. Take the Precision Peptide Genetic Test, or explore the Weight Management Protocols.

Frequently Asked Questions

Where do Zepbound and Mounjaro sit among GLP-1 options?

Both are tirzepatide, the GIP/GLP-1 dual agonist, placing them alongside GLP-1-selective agents like semaglutide and liraglutide in the broader incretin field. Within that landscape they share a coordinate — one molecule under two labels — separated only by the FDA indication each brand carries.

Since they're the same molecule, why compare them at all?

The comparison is really about indication and access, not pharmacology. Mounjaro holds the diabetes label and Zepbound the weight-management and sleep-apnea labels, and that distinction shapes prescribing, coverage, and cost even though the underlying tirzepatide is identical.

How does pricing work across this landscape?

List prices for FDA-approved brands span roughly $815 to $1,620 per month as of April 2026. Because coverage often follows indication, the out-of-pocket figure varies widely between diabetes and weight-management prescriptions, and compounded pathways add another option with separate pricing and oversight.

What does the Precision Peptide Genetic Test add?

It supplies upstream context. The test analyzes pathway-level variants in FTO, GLP1R, MC4R, and TCF7L2 that describe your baseline metabolic biology — information that applies across the whole GLP-1 landscape. It is educational and does not predict response to tirzepatide or any specific medication.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.